Suppression of metastasis due to regulation of PETA3/CD151

CD151与一个令人兴奋的基因PETA-3相同，可能促进恶性细胞的肿瘤转移，其表达可能参与肿瘤的恶性进展。先前，我们发现MRP- 1/CD9，跨膜4超家族（TM4SF）的成员，抑制细胞运动和肺转移潜能。此外，MRP-i/CD9基因表达降低是非小细胞肺癌患者预后不良的一个因素，TM4SF的另一个成员KAI1/CD82也是如此。在此基础上，我们采用RT-PCR和免疫组织化学技术对145例肺癌患者肿瘤组织中GD15I基因的表达进行回顾性研究；其中I期72例，II期29例，IIIA期27例，IIIB期17例，CD151基因阳性肿瘤86例，CD151基因阴性肿瘤59例。CD151阳性肿瘤患者的总生存率明显低于CD151阴性肿瘤患者（51.9% vs 73.1%; p= 0.13）。同样，CD151阳性腺癌患者的总生存率远低于CD151阴性患者（47.4% vs 71.9%; p= 0.47）。Cox回归模型多因素分析显示，除淋巴结状态和肿瘤状态外，CD151阳性与总生存率相关性最强。我们的研究结果表明，CD151基因在肺癌中的高表达可能与预后不良有关。CD151的评估可能有助于改善肺癌的诊断和治疗。此外，我们研究了146名接受治疗性手术的结肠癌患者。PETA-3/CD151的表达与肿瘤状态有显著关系。PETA-3/CD151阳性表达对结肠癌患者的总生存率有不良影响（P = 0.022）。

CD151 is identical to an exciting gene PETA-3 which may promote tumor metastasis of malignant cells and its expression may be involved in the malignant progression cancer. Previously, we found that MRP- 1/CD9, a member of the transmembrane 4 superfamily (TM4SF), suppressed cell motility and metastatic potential to lungs. Moreover, reduction of MRP-i/CD9 gene expression was found to be a factor of a poor prognosis for the patients with non-small cell lung cancer, as was another member of TM4SF, KAI1/CD82.On the basis of these results, we used RT-PCR and immunohistochemical technique for a retrospective study of GD15I gene expression in tumor tissues from 145 lung cancer patients ; 72 tumors were stage I, 29 stage II, 27 stage IIIA and 17 stage IIIB While 8 6 patients had the tumors with positive CD151 gene, 59 had the negative CD151 gene tumors. The overall survival rate of patients with CD151 positive tumors was much lower than that of CD151 negative patients (51.9% vs 73.1 % ; p=O.O13). Similarly, the overall survival rate of CD151 positive patients with adenocarcinoma was much lower than that of CD151 negative patients (47.4% vs 71.9% ; p=O.O47). Multivariate analysis with the Cox regression model indicated that CD151 positivity correlated best with the overall survival rate except lymph node status and tumor status. Our findings suggest that high CD151 gene expression in lung cancer may be associated with a poor prognosis. Assessment of CD151 could be instrumental for improvements in lung cancer diagnosis and therapies. In addition, we studied 146 colon cancer patients who underwent curative surgery. A significant relationship was found between PETA-3/CD151 expression and tumor status. Positive PETA-3/CD151 expression had a bad effect on the overall survival rate of patients with colon cancer (P = 0.022).